Integration analysis of tumor metagenome and peripheral immunity data of diffuse large-B cell lymphomaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the gut microbiota landscape of patients with diffuse large B-cell lymphoma (DLBCL) and its relationship to peripheral blood immune cell subtypes. Researchers used metagenomic sequencing to characterize gut bacterial composition and full-spectral flow cytometry to profile immune cell subsets. The goal was to identify microbiota and immune features that differ across NCCN-International Prognostic Index (NCCN-IPI) risk categories, since the gut microbe landscape in DLBCL and its link to immunity had remained largely unknown.
Who was studied?
A total of 87 newly diagnosed adult DLBCL patients were enrolled and had peripheral blood samples collected for immune cell subtyping. Of these, 69 of the 87 patients also had stool or tumor-associated samples submitted for metagenomic sequencing to assess microbiota composition. Patients were grouped according to NCCN-IPI risk categories: low-risk, low-intermediate-risk, intermediate-high-risk, and high-risk.
What were the most important findings?
Metagenomic sequencing identified 10 bacterial phyla, 31 orders, and 455 bacterial species across the 69 profiled DLBCL patients. Six bacteria showed abundance differences of note, including Blautia sp. CAG 257, Actinomyces sp. S6 Spd3, Streptococcus parasanguinis, Bacteroides salyersiae, and Enterococcus faecalis. The abstract does not mention Bacteroides fragilis, polysaccharide A, or the B. fragilis toxin, so this study's findings center on other bacterial taxa and their association with NCCN-IPI risk groups and peripheral immune cell subsets.
What are the greatest implications of this study?
By linking specific gut bacterial abundances to NCCN-IPI prognostic risk groups and peripheral immune cell subtypes, this work suggests the gut microbiome may play a role in shaping immune status and disease risk stratification in DLBCL. These integrated microbiome-immune signatures could eventually inform prognostic tools or risk-adapted monitoring for newly diagnosed patients. Further validation would be needed before such microbiota features could guide clinical decision-making in lymphoma care.